Kobalava Zh D, Kotovskaya Yu V, Bogomaz A V
Peoples Friendship University of Russia, Moscow, Russia.
Kardiologiia. 2015 Dec;55(12):11-16. doi: 10.18565/cardio.2015.12.11-16.
to assess effect of -blockers in the characteristics of the central pulse wave and the effect of switching to a fixed bisoprolol/amlodipine (B/A) combination.
Untreated patients (n=28, age 53.6+/-5.7 years, 19 men) with uncomplicated hypertension without diabetes were given bisoprolol 5-10 mg. After 4 weeks at blood pressure (BP) >40/90 mmHg amlodipine (5 mg) was added by switching to a fixed B/A combination. The dose of amlodipine in this combination was increased to 10 mg in order to achieve target BP. The duration of combination therapy was 8 weeks. Analysis of the contour of central pulse wave and measurement of pulse wave velocity between carotid and femoral arteries (PWV) were evaluated before treatment, after monotherapy with bisoprolol, and after therapy with fixed B/A combination.
After monotherapy with bisoprolol 5 patients achieved BP control, 23 were switched to a fixed B/A combination. Monotherapy with bisoprolol reduced mainly peripheral BP and increased augmentation index (AI) of aortic pulse pressure, normalized to heart rate of 75 beats/min (AI-75). Switching to a fixed B/A combination resulted in further reduction of peripheral BP and significantly greater lowering of central systolic and pulse pressure, return of AI-75 to baseline values, significant decrease of PWVCA.
Switching to a fixed B/A combination eliminates the potentially undesirable effects of -blockers on the parameters of the reflected wave, thus resulting in effective lowering of central systolic and pulse BP, and reduction of PWV.
评估β受体阻滞剂对中心脉搏波特征的影响以及转换为固定剂量的比索洛尔/氨氯地平(B/A)联合用药的效果。
选取28例无并发症、无糖尿病的未治疗高血压患者(年龄53.6±5.7岁,男性19例),给予比索洛尔5 - 10 mg。4周后,若血压(BP)>140/90 mmHg,则加用氨氯地平(5 mg),转换为固定的B/A联合用药。为达到目标血压,将该联合用药中氨氯地平的剂量增至10 mg。联合治疗持续8周。在治疗前、比索洛尔单药治疗后以及固定B/A联合用药治疗后,评估中心脉搏波轮廓分析以及颈动脉与股动脉之间脉搏波速度(PWV)的测量结果。
比索洛尔单药治疗后,5例患者血压得到控制,23例转换为固定的B/A联合用药。比索洛尔单药治疗主要降低外周血压,增加主动脉脉压的增强指数(AI),以心率75次/分钟进行标准化(AI-75)。转换为固定的B/A联合用药导致外周血压进一步降低,中心收缩压和脉压显著更大程度降低,AI-75恢复至基线值,PWVCA显著降低。
转换为固定的B/A联合用药可消除β受体阻滞剂对反射波参数的潜在不良影响,从而有效降低中心收缩压和脉压,并降低PWV。